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Abstract
Two recently reported randomized studies discussed below are paving the way for personalized
treatment approaches for patients with non-small cell lung cancer (NSCLC). Both studies show that
accurate subclassification of NSCLC will become necessary to prescribe chemotherapy doublets and
epidermal growth factor receptor tyrosine kinase inhibitors. It is expected that the practice of the last
30 years of lumping all NSCLC subtypes together will soon come to an end.
Introduction and context
Lung cancer is the leading cause of cancer death in the
world and progress in the treatment of the different
diseases under this heading has been modest in the last
25 years. The two most important reasons for the lack of
progress are the fact that the majority of patients with
lung cancer present with advanced (metastatic) disease
and that responses to systemic therapy most frequently
are partial and of relatively short duration. About 85% of
all patients with lung cancer have ‘non-small cell’
histology, and international guidelines indicate that
four cycles of so-called platinum doublet chemotherapy
are standard. These guidelines do not address histology
or which platinum doublet.
Recent advances
A recent study has shown that pemetrexed/cisplatin was
superior to gemcitabine/cisplatin in two subgroups of
patients with non-small cell lung cancer (NSCLC):
adenocarcinoma and large cell carcinoma. The gemcita-
bine/cisplatin combination performed better in patients
with squamous cell carcinoma [1]. This important
observation (that is, the increased sensitivity to specific
chemotherapeutic agents in subgroups of patients with
NSCLC) has been confirmed recently by others [2,3]. The
main target of pemetrexed is thymidylate synthase (TS).
In NSCLC patients who underwent surgical resection, TS
is expressed at a higher level in squamous cell carcinoma
than in adenocarcinoma and this may well explain the
better result of pemetrexed in adenocarcinoma.
These recent study results show that the oncological
community now has the opportunity to leave the current
practice of lumping different histologies together and to
prescribe cytotoxic drugs on clinicopathological para-
meters. The art of selecting systemic therapy for NSCLC
lies not only in knowing which drugs to use but also in
the selection of subgroups of patients who are most
likely to benefit from the treatment.
Another category of systemic agents for NSCLC is
composed of oral tyrosine kinase inhibitors of the
epidermal growth factor receptor (otherwise known as
EGFR-TKIs). Two EGFR-TKIs, erlotinib and gefitinib,
have been studied extensively in the last 6-7 years and
were found to induce responses, improve symptoms,
and in some instances to prolong survival in previously
treated patients with NSCLC [4,5]. During early clinical
development of the two drugs, it had become apparent
that patients with adenocarcinoma and patients with
little or no exposure to cigarette smoke had better
responses to these two agents; moreover, Southeast Asian
patients seemed to respond better [6].
In 2004, independent groups of investigators suggested
that increased sensitivity to EGFR inhibitors was related
to specific mutations in the EGFR domain [7,8].
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gefitinib in patients with EGFR mutations seemed to
confirm this hypothesis [9], and very recently a
randomized study revealed that gefitinib performs better
than chemotherapy in a preselected group of Asian
patients with adenocarcinoma (light or never smokers)
with an EGFR mutation, whereas patients without a
mutation had a more favourable result on chemotherapy
[10].
Implications for clinical practice
Thus, there are multiple indications for the abandon-
ment of the common practice of the last three decades of
offering the same treatment to all patients with NSCLC.
The studies cited above provide enough evidence to start
using histology and mutation status as criteria for patient
selection. The practical consequence of that will be a
decrease in popularity of the fine-needle aspiration
technique for diagnosis. Most likely, a cytological
diagnosis will not be firm enough to serve as the basis
for treatment advice in the near future. It is also worth
mentioning that the determination of EGFR mutation
status is quite laborious and needs an experienced hand.
Therefore, it is generally felt that this selection criterion is
not easily accessible to all oncology units. Solutions such
as the introduction of specific diagnostic kits for EGFR
mutations are currently being investigated.
The selection of subgroups of patients with NSCLC for
therapy is becoming increasingly important. It is equally
important to identify patients who are not likely to
respond or live longer as a result of therapy. This is
especially relevant for treatments related with significant
toxicity or for which the cost-benefit ratio of the
treatment is likely to be extremely high. An individua-
lized treatment approach is becoming an important issue
in NSCLC.
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